LeMaitre's Q2 Growth Is Real-But the Missing Quarter Made the Downside Hurts

Q2 results were operationally solid but still missed the tape

The contradiction investors have to live with

LeMaitre's latest quarter looks like a good business behind a weak print. Sales still rose 10% to $70.4 million, gross margin reached 72.1%, and operating margin was 29%. Those are not the marks of a business falling apart. But the market reaction was still negative because revenue missed expectations and GAAP EPS of $0.74 came in below consensus. In other words, the quarter looked bad on paper even if the underlying business did not.

Why the call mattered more than Q1's modest beat

That makes the commentary following the release the real test. In Q1, LeMaitre at least beat expectations, which leaves some goodwill with investors. This time, management had to explain why a cleanly improving quarter still disappointed. The bigger issue was guidance: the company cut full-year revenue guidance to a midpoint of $276.3 million from $280 million. Bears can frame that as a tempo problem. Bulls can argue it is mostly a reset after a missed quarter, not a broken growth engine.

The business still looked healthy inside the headline miss

Growth was still coming from the right products

This was not a broad-based softness story. LeMaitre still grew sales 10% to $70.4 million, and several core product lines kept setting records. Grafts rose 23%, Artegraft sales increased 34%, carotid shunts rose 18%, and patches increased 4%. That suggests the demand base is still intact rather than broadly weakening.

Artegraft remains the clearest signal. It now accounts for 21% of sales, which supports management's point that the company's largest product is also its fastest-growing one. That is generally a constructive setup because a growing lead product can help lift the rest of the portfolio.

Catheters were down 11%, which is why reported organic growth came in at 10%. But LeMaitre also said Q2 organic growth was 12% excluding catheters, after a prior-year recall drove overstocking. A fairer read is not that growth is breaking; it is that one distorted category is pulling down the headline.

Margins still showed operating leverage

The profit picture also looked solid. Gross margin was 72.1%, up 210 basis points, driven by pricing, mix, and operational efficiencies. Operating income rose to $20.4 million, while headcount stayed essentially flat year over year at 660 at 6/30/2026 vs. 658 at 6/30/2025. That is a reasonable sign of operating leverage: more profit coming through without a matching rise in people costs.

Q1 looked broadly similar, with sales up 11% and gross margin of 72.7%. The takeaway is not that Q2 was unusually strong. It is that there was no clear breakdown across products and margins at the same time.

Why the stock reaction was harsher than the business news

The market still focused on the scoreboard. LeMaitre missed Q2 revenue expectations, EPS came in below the strip, and the stock dropped 11.6%. That is the cost of missing the quarter, even when the operating fundamentals still look reasonable.

If the next few quarters show the same mix of demand, pricing, and margin discipline, the stock has a path to stop treating one weak print like a weak business.

What would help the stock recover from here

The follow-through after the conference call matters more than the headline miss itself. LeMaitre does not need help with capital: it ended the quarter with $376.2 million of cash. What it needs is for investors to view the miss as a timing setback rather than the start of a slower phase of growth. After Q1 beat expectations, that distinction is especially important.

What investors should watch next

• Whether Artegraft keeps becoming the main growth engine. The product already accounts for 21% of sales, so the key question is whether that momentum can keep lifting reported growth and offset weaker pockets such as catheters.
• Whether margins stay above the low-70% range. Gross margin was 72.1% in Q2 and 72.7% in Q1. If that level holds, it would support the view that pricing and operating discipline are still intact.
• Whether guidance gets cut again. The company already dropped its revenue guidance for the full year to $276.3 million at the midpoint from $280 million. Another reduction would make it harder to argue that this was only a one-quarter reset.